‘Miracle’ Alzheimer’s drug WON’T be offered on the NHS after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year

August 22, 2024

It was today approved by the medicines regulator. But draft guidance by the UK’s drugs watchdog ruled the benefits of the drug ‘are too small to justify the costs’.

https://www.dailymail.co.uk/health/article-13768255/Miracle-Alzheimers-drug-WONT-offered-NHS-drug-watchdog-rules-benefits-small-justify-eye-watering-1bn-year-roll-cost-available-private-patients-pay-20-000-year.html?ns_mchannel=rss&ns_campaign=1490&ito=1490

‘Miracle’ Alzheimer’s drug WON’T be offered on the NHS after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year <body> <h1> Array ( [0] => ᰰmiracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [1] => &#u216;miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [2] => &#i216;miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [3] => ␀miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [4] => ᾴmiracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [5] => &#8q16;miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [6] => &#8w16;miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [7] => ⁼miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [8] => •miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [9] => &#82q6;miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [10] => ‗miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [11] => &#821t;miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [12] => &#821y;miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [13] => ’miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [14] => ‘niracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [15] => ‘kiracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [16] => ‘jiracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [17] => ‘muracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [18] => ‘mjracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [19] => ‘mkracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [20] => ‘moracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [21] => ‘m9racle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [22] => ‘m8racle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [23] => ‘mieacle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [24] => ‘midacle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [25] => ‘mifacle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [26] => ‘mitacle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [27] => ‘mi5acle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [28] => ‘mi4acle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [29] => ‘mirzcle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [30] => ‘mirscle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [31] => ‘mirwcle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [32] => ‘mirqcle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [33] => ‘miraxle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [34] => ‘miravle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [35] => ‘mirafle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [36] => ‘miradle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [37] => ‘miracke’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [38] => ‘miracpe’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [39] => ‘miracoe’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [40] => ‘miraclw’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [41] => ‘miracls’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [42] => ‘miracld’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [43] => ‘miraclr’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [44] => ‘miracl4’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [45] => ‘miracl3’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [46] => ‘miracleᰱ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [47] => ‘miracle&#u217; alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [48] => ‘miracle&#i217; alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [49] => ‘miracle␁ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [50] => ‘miracle᾵ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [51] => ‘miracle&#8q17; alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [52] => ‘miracle&#8w17; alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [53] => ‘miracle⁽ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [54] => ‘miracle‣ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [55] => ‘miracle&#82q7; alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [56] => ‘miracle‘ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [57] => ‘miracle&#821y; alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [58] => ‘miracle&#821u; alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [59] => ‘miracle‚ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [60] => ‘miracle’ zlzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [61] => ‘miracle’ slzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [62] => ‘miracle’ wlzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [63] => ‘miracle’ qlzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [64] => ‘miracle’ akzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [65] => ‘miracle’ apzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [66] => ‘miracle’ aozheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [67] => ‘miracle’ alxheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [68] => ‘miracle’ alsheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [69] => ‘miracle’ alaheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [70] => ‘miracle’ alzgeimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [71] => ‘miracle’ alzbeimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [72] => ‘miracle’ alzneimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [73] => ‘miracle’ alzjeimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [74] => ‘miracle’ alzueimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [75] => ‘miracle’ alzyeimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [76] => ‘miracle’ alzhwimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [77] => ‘miracle’ alzhsimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [78] => ‘miracle’ alzhdimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [79] => ‘miracle’ alzhrimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [80] => ‘miracle’ alzh4imer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [81] => ‘miracle’ alzh3imer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [82] => ‘miracle’ alzheumer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [83] => ‘miracle’ alzhejmer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [84] => ‘miracle’ alzhekmer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [85] => ‘miracle’ alzheomer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [86] => ‘miracle’ alzhe9mer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [87] => ‘miracle’ alzhe8mer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [88] => ‘miracle’ alzheiner’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [89] => ‘miracle’ alzheiker’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [90] => ‘miracle’ alzheijer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [91] => ‘miracle’ alzheimwr’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [92] => ‘miracle’ alzheimsr’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [93] => ‘miracle’ alzheimdr’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [94] => ‘miracle’ alzheimrr’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [95] => ‘miracle’ alzheim4r’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [96] => ‘miracle’ alzheim3r’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [97] => ‘miracle’ alzheimee’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [98] => ‘miracle’ alzheimed’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [99] => ‘miracle’ alzheimef’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [100] => ‘miracle’ alzheimet’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [101] => ‘miracle’ alzheime5’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [102] => ‘miracle’ alzheime4’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [103] => ‘miracle’ alzheimerᰱs drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [104] => ‘miracle’ alzheimer&#u217;s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [105] => ‘miracle’ alzheimer&#i217;s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [106] => ‘miracle’ alzheimer␁s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [107] => ‘miracle’ alzheimer᾵s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [108] => ‘miracle’ alzheimer&#8q17;s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [109] => ‘miracle’ alzheimer&#8w17;s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [110] => ‘miracle’ alzheimer⁽s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [111] => ‘miracle’ alzheimer‣s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [112] => ‘miracle’ alzheimer&#82q7;s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [113] => ‘miracle’ alzheimer‘s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [114] => ‘miracle’ alzheimer&#821y;s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [115] => ‘miracle’ alzheimer&#821u;s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [116] => ‘miracle’ alzheimer‚s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [117] => ‘miracle’ alzheimer’a drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [118] => ‘miracle’ alzheimer’z drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [119] => ‘miracle’ alzheimer’x drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [120] => ‘miracle’ alzheimer’d drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [121] => ‘miracle’ alzheimer’e drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [122] => ‘miracle’ alzheimer’w drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [123] => ‘miracle’ alzheimer’s srug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [124] => ‘miracle’ alzheimer’s xrug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [125] => ‘miracle’ alzheimer’s crug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [126] => ‘miracle’ alzheimer’s frug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [127] => ‘miracle’ alzheimer’s rrug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [128] => ‘miracle’ alzheimer’s erug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [129] => ‘miracle’ alzheimer’s deug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [130] => ‘miracle’ alzheimer’s ddug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [131] => ‘miracle’ alzheimer’s dfug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [132] => ‘miracle’ alzheimer’s dtug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [133] => ‘miracle’ alzheimer’s d5ug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [134] => ‘miracle’ alzheimer’s d4ug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [135] => ‘miracle’ alzheimer’s dryg won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [136] => ‘miracle’ alzheimer’s drhg won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [137] => ‘miracle’ alzheimer’s drjg won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [138] => ‘miracle’ alzheimer’s drig won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [139] => ‘miracle’ alzheimer’s dr8g won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [140] => ‘miracle’ alzheimer’s dr7g won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [141] => ‘miracle’ alzheimer’s druf won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [142] => ‘miracle’ alzheimer’s druv won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [143] => ‘miracle’ alzheimer’s drub won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [144] => ‘miracle’ alzheimer’s druh won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [145] => ‘miracle’ alzheimer’s druy won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [146] => ‘miracle’ alzheimer’s drut won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [147] => ‘miracle’ alzheimer’s drug qon’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [148] => ‘miracle’ alzheimer’s drug aon’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [149] => ‘miracle’ alzheimer’s drug son’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [150] => ‘miracle’ alzheimer’s drug eon’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [151] => ‘miracle’ alzheimer’s drug 3on’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [152] => ‘miracle’ alzheimer’s drug 2on’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [153] => ‘miracle’ alzheimer’s drug win’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [154] => ‘miracle’ alzheimer’s drug wkn’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [155] => ‘miracle’ alzheimer’s drug wln’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [156] => ‘miracle’ alzheimer’s drug wpn’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [157] => ‘miracle’ alzheimer’s drug w0n’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [158] => ‘miracle’ alzheimer’s drug w9n’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [159] => ‘miracle’ alzheimer’s drug wob’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [160] => ‘miracle’ alzheimer’s drug wom’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [161] => ‘miracle’ alzheimer’s drug woj’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [162] => ‘miracle’ alzheimer’s drug woh’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [163] => ‘miracle’ alzheimer’s drug wonᰱt be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [164] => ‘miracle’ alzheimer’s drug won&#u217;t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [165] => ‘miracle’ alzheimer’s drug won&#i217;t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [166] => ‘miracle’ alzheimer’s drug won␁t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [167] => ‘miracle’ alzheimer’s drug won᾵t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [168] => ‘miracle’ alzheimer’s drug won&#8q17;t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [169] => ‘miracle’ alzheimer’s drug won&#8w17;t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [170] => ‘miracle’ alzheimer’s drug won⁽t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [171] => ‘miracle’ alzheimer’s drug won‣t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [172] => ‘miracle’ alzheimer’s drug won&#82q7;t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [173] => ‘miracle’ alzheimer’s drug won‘t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [174] => ‘miracle’ alzheimer’s drug won&#821y;t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [175] => ‘miracle’ alzheimer’s drug won&#821u;t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [176] => ‘miracle’ alzheimer’s drug won‚t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [177] => ‘miracle’ alzheimer’s drug won’r be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [178] => ‘miracle’ alzheimer’s drug won’f be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [179] => ‘miracle’ alzheimer’s drug won’g be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [180] => ‘miracle’ alzheimer’s drug won’y be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [181] => ‘miracle’ alzheimer’s drug won’6 be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [182] => ‘miracle’ alzheimer’s drug won’5 be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [183] => ‘miracle’ alzheimer’s drug won’t ve offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [184] => ‘miracle’ alzheimer’s drug won’t ne offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [185] => ‘miracle’ alzheimer’s drug won’t he offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [186] => ‘miracle’ alzheimer’s drug won’t ge offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [187] => ‘miracle’ alzheimer’s drug won’t bw offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [188] => ‘miracle’ alzheimer’s drug won’t bs offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [189] => ‘miracle’ alzheimer’s drug won’t bd offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [190] => ‘miracle’ alzheimer’s drug won’t br offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [191] => ‘miracle’ alzheimer’s drug won’t b4 offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [192] => ‘miracle’ alzheimer’s drug won’t b3 offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [193] => ‘miracle’ alzheimer’s drug won’t be iffered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [194] => ‘miracle’ alzheimer’s drug won’t be kffered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [195] => ‘miracle’ alzheimer’s drug won’t be lffered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [196] => ‘miracle’ alzheimer’s drug won’t be pffered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [197] => ‘miracle’ alzheimer’s drug won’t be 0ffered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [198] => ‘miracle’ alzheimer’s drug won’t be 9ffered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [199] => ‘miracle’ alzheimer’s drug won’t be odfered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [200] => ‘miracle’ alzheimer’s drug won’t be ocfered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [201] => ‘miracle’ alzheimer’s drug won’t be ovfered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [202] => ‘miracle’ alzheimer’s drug won’t be ogfered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [203] => ‘miracle’ alzheimer’s drug won’t be otfered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [204] => ‘miracle’ alzheimer’s drug won’t be orfered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [205] => ‘miracle’ alzheimer’s drug won’t be ofdered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [206] => ‘miracle’ alzheimer’s drug won’t be ofcered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [207] => ‘miracle’ alzheimer’s drug won’t be ofvered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [208] => ‘miracle’ alzheimer’s drug won’t be ofgered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [209] => ‘miracle’ alzheimer’s drug won’t be oftered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [210] => ‘miracle’ alzheimer’s drug won’t be ofrered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [211] => ‘miracle’ alzheimer’s drug won’t be offwred on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [212] => ‘miracle’ alzheimer’s drug won’t be offsred on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [213] => ‘miracle’ alzheimer’s drug won’t be offdred on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [214] => ‘miracle’ alzheimer’s drug won’t be offrred on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [215] => ‘miracle’ alzheimer’s drug won’t be off4red on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [216] => ‘miracle’ alzheimer’s drug won’t be off3red on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [217] => ‘miracle’ alzheimer’s drug won’t be offeeed on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [218] => ‘miracle’ alzheimer’s drug won’t be offeded on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [219] => ‘miracle’ alzheimer’s drug won’t be offefed on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [220] => ‘miracle’ alzheimer’s drug won’t be offeted on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [221] => ‘miracle’ alzheimer’s drug won’t be offe5ed on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [222] => ‘miracle’ alzheimer’s drug won’t be offe4ed on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [223] => ‘miracle’ alzheimer’s drug won’t be offerwd on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [224] => ‘miracle’ alzheimer’s drug won’t be offersd on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [225] => ‘miracle’ alzheimer’s drug won’t be offerdd on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [226] => ‘miracle’ alzheimer’s drug won’t be offerrd on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [227] => ‘miracle’ alzheimer’s drug won’t be offer4d on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [228] => ‘miracle’ alzheimer’s drug won’t be offer3d on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [229] => ‘miracle’ alzheimer’s drug won’t be offeres on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [230] => ‘miracle’ alzheimer’s drug won’t be offerex on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [231] => ‘miracle’ alzheimer’s drug won’t be offerec on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [232] => ‘miracle’ alzheimer’s drug won’t be offeref on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [233] => ‘miracle’ alzheimer’s drug won’t be offerer on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [234] => ‘miracle’ alzheimer’s drug won’t be offeree on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [235] => ‘miracle’ alzheimer’s drug won’t be offered in the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [236] => ‘miracle’ alzheimer’s drug won’t be offered kn the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [237] => ‘miracle’ alzheimer’s drug won’t be offered ln the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [238] => ‘miracle’ alzheimer’s drug won’t be offered pn the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [239] => ‘miracle’ alzheimer’s drug won’t be offered 0n the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [240] => ‘miracle’ alzheimer’s drug won’t be offered 9n the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [241] => ‘miracle’ alzheimer’s drug won’t be offered ob the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [242] => ‘miracle’ alzheimer’s drug won’t be offered om the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [243] => ‘miracle’ alzheimer’s drug won’t be offered oj the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [244] => ‘miracle’ alzheimer’s drug won’t be offered oh the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [245] => ‘miracle’ alzheimer’s drug won’t be offered on rhe nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [246] => ‘miracle’ alzheimer’s drug won’t be offered on fhe nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [247] => ‘miracle’ alzheimer’s drug won’t be offered on ghe nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [248] => ‘miracle’ alzheimer’s drug won’t be offered on yhe nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [249] => ‘miracle’ alzheimer’s drug won’t be offered on 6he nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [250] => ‘miracle’ alzheimer’s drug won’t be offered on 5he nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [251] => ‘miracle’ alzheimer’s drug won’t be offered on tge nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [252] => ‘miracle’ alzheimer’s drug won’t be offered on tbe nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [253] => ‘miracle’ alzheimer’s drug won’t be offered on tne nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [254] => ‘miracle’ alzheimer’s drug won’t be offered on tje nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [255] => ‘miracle’ alzheimer’s drug won’t be offered on tue nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [256] => ‘miracle’ alzheimer’s drug won’t be offered on tye nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [257] => ‘miracle’ alzheimer’s drug won’t be offered on thw nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [258] => ‘miracle’ alzheimer’s drug won’t be offered on ths nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [259] => ‘miracle’ alzheimer’s drug won’t be offered on thd nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [260] => ‘miracle’ alzheimer’s drug won’t be offered on thr nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [261] => ‘miracle’ alzheimer’s drug won’t be offered on th4 nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [262] => ‘miracle’ alzheimer’s drug won’t be offered on th3 nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [263] => ‘miracle’ alzheimer’s drug won’t be offered on the bhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [264] => ‘miracle’ alzheimer’s drug won’t be offered on the mhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [265] => ‘miracle’ alzheimer’s drug won’t be offered on the jhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [266] => ‘miracle’ alzheimer’s drug won’t be offered on the hhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [267] => ‘miracle’ alzheimer’s drug won’t be offered on the ngs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [268] => ‘miracle’ alzheimer’s drug won’t be offered on the nbs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [269] => ‘miracle’ alzheimer’s drug won’t be offered on the nns after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [270] => ‘miracle’ alzheimer’s drug won’t be offered on the njs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [271] => ‘miracle’ alzheimer’s drug won’t be offered on the nus after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [272] => ‘miracle’ alzheimer’s drug won’t be offered on the nys after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [273] => ‘miracle’ alzheimer’s drug won’t be offered on the nha after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [274] => ‘miracle’ alzheimer’s drug won’t be offered on the nhz after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [275] => ‘miracle’ alzheimer’s drug won’t be offered on the nhx after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [276] => ‘miracle’ alzheimer’s drug won’t be offered on the nhd after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [277] => ‘miracle’ alzheimer’s drug won’t be offered on the nhe after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [278] => ‘miracle’ alzheimer’s drug won’t be offered on the nhw after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [279] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs zfter drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [280] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs sfter drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [281] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs wfter drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [282] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs qfter drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [283] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs adter drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [284] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs acter drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [285] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs avter drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [286] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs agter drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [287] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs atter drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [288] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs arter drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [289] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs afrer drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [290] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs affer drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [291] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs afger drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [292] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs afyer drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [293] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs af6er drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [294] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs af5er drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [295] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs aftwr drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [296] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs aftsr drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [297] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs aftdr drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [298] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs aftrr drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [299] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs aft4r drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [300] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs aft3r drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [301] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs aftee drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [302] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs afted drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [303] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs aftef drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [304] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs aftet drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [305] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs afte5 drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [306] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs afte4 drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [307] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after srug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [308] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after xrug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [309] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after crug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [310] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after frug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [311] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after rrug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [312] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after erug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [313] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after deug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [314] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after ddug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [315] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after dfug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [316] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after dtug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [317] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after d5ug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [318] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after d4ug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [319] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after dryg watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [320] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drhg watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [321] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drjg watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [322] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drig watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [323] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after dr8g watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [324] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after dr7g watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [325] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after druf watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [326] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after druv watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [327] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drub watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [328] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after druh watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [329] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after druy watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [330] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drut watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [331] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug qatchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [332] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug aatchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [333] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug satchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [334] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug eatchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [335] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug 3atchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [336] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug 2atchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [337] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug wztchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [338] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug wstchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [339] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug wwtchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [340] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug wqtchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [341] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug warchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [342] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug wafchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [343] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug wagchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [344] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug waychdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [345] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug wa6chdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [346] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug wa5chdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [347] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watxhdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [348] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watvhdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [349] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watfhdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [350] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watdhdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [351] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watcgdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [352] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watcbdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [353] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watcndog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [354] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watcjdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [355] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watcudog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [356] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watcydog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [357] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchsog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [358] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchxog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [359] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchcog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [360] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchfog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [361] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchrog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [362] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watcheog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [363] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdig rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [364] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdkg rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [365] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdlg rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [366] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdpg rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [367] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchd0g rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [368] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchd9g rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [369] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdof rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [370] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdov rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [371] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdob rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [372] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdoh rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [373] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdoy rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [374] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdot rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [375] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog eules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [376] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog dules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [377] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog fules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [378] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog tules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [379] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog 5ules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [380] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog 4ules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [381] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog ryles benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [382] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rhles benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [383] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rjles benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [384] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog riles benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [385] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog r8les benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [386] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog r7les benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [387] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rukes benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [388] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rupes benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [389] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog ruoes benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [390] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rulws benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [391] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rulss benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [392] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rulds benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [393] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rulrs benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [394] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rul4s benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [395] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rul3s benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [396] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rulea benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [397] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rulez benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [398] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rulex benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [399] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog ruled benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [400] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rulee benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [401] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rulew benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [402] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules venefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [403] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules nenefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [404] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules henefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [405] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules genefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [406] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules bwnefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [407] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules bsnefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [408] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules bdnefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [409] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules brnefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [410] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules b4nefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [411] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules b3nefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [412] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules bebefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [413] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules bemefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [414] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules bejefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [415] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules behefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [416] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benwfits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [417] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules bensfits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [418] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules bendfits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [419] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benrfits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [420] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules ben4fits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [421] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules ben3fits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [422] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benedits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [423] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benecits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [424] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benevits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [425] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benegits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [426] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benetits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [427] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benerits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [428] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefuts are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [429] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefjts are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [430] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefkts are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [431] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefots are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [432] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benef9ts are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [433] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benef8ts are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [434] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefirs are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [435] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefifs are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [436] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefigs are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [437] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefiys are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [438] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefi6s are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [439] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefi5s are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [440] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefita are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [441] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefitz are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [442] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefitx are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [443] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefitd are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [444] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefite are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [445] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefitw are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [446] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits zre too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [447] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits sre too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [448] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits wre too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [449] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits qre too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [450] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits aee too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [451] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits ade too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [452] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits afe too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [453] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits ate too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [454] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits a5e too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [455] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits a4e too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [456] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits arw too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [457] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits ars too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [458] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits ard too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [459] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits arr too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [460] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits ar4 too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [461] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits ar3 too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [462] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are roo small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [463] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are foo small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [464] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are goo small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [465] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are yoo small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [466] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are 6oo small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [467] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are 5oo small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [468] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are tio small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [469] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are tko small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [470] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are tlo small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [471] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are tpo small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [472] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are t0o small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [473] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are t9o small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [474] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are toi small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [475] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are tok small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [476] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are tol small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [477] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are top small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [478] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are to0 small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [479] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are to9 small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [480] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too amall to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [481] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too zmall to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [482] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too xmall to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [483] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too dmall to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [484] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too emall to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [485] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too wmall to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [486] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too snall to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [487] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too skall to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [488] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too sjall to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [489] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too smzll to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [490] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too smsll to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [491] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too smwll to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [492] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too smqll to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [493] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too smakl to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [494] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too smapl to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [495] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too smaol to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [496] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too smalk to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [497] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too smalp to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [498] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too smalo to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [499] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small ro justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [500] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small fo justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [501] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small go justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [502] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small yo justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [503] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small 6o justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [504] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small 5o justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [505] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small ti justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [506] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small tk justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [507] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small tl justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [508] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small tp justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [509] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small t0 justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [510] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small t9 justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [511] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to hustify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [512] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to nustify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [513] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to mustify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [514] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to kustify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [515] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to iustify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [516] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to uustify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [517] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to jystify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [518] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to jhstify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [519] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to jjstify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [520] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to jistify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [521] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to j8stify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [522] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to j7stify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [523] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to juatify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [524] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to juztify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [525] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to juxtify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [526] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to judtify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [527] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to juetify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [528] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to juwtify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [529] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to jusrify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [530] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to jusfify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [531] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to jusgify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [532] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to jusyify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [533] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to jus6ify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [534] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to jus5ify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [535] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justufy the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [536] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justjfy the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [537] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justkfy the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [538] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justofy the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [539] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to just9fy the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [540] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to just8fy the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [541] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justidy the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [542] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justicy the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [543] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justivy the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [544] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justigy the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [545] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justity the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [546] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justiry the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [547] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justift the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [548] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justifg the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [549] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justifh the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [550] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justifu the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [551] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justif7 the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [552] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justif6 the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [553] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify rhe eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [554] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify fhe eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [555] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify ghe eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [556] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify yhe eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [557] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify 6he eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [558] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify 5he eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [559] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify tge eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [560] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify tbe eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [561] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify tne eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [562] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify tje eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [563] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify tue eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [564] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify tye eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [565] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify thw eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [566] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify ths eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [567] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify thd eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [568] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify thr eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [569] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify th4 eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [570] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify th3 eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [571] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the wye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [572] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the sye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [573] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the dye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [574] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the rye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [575] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the 4ye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [576] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the 3ye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [577] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the ete-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [578] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the ege-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [579] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the ehe-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [580] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eue-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [581] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the e7e-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [582] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the e6e-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [583] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eyw-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [584] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eys-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [585] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eyd-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [586] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eyr-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [587] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the ey4-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [588] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the ey3-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [589] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye0watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [590] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eyepwatering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [591] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-qatering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [592] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-aatering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [593] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-satering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [594] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-eatering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [595] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-3atering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [596] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-2atering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [597] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-wztering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [598] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-wstering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [599] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-wwtering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [600] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-wqtering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [601] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-warering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [602] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-wafering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [603] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-wagering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [604] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-wayering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [605] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-wa6ering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [606] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-wa5ering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [607] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watwring ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [608] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watsring ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [609] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watdring ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [610] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watrring ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [611] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-wat4ring ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [612] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-wat3ring ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [613] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-wateeing ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [614] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-wateding ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [615] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watefing ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [616] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-wateting ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [617] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-wate5ing ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [618] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-wate4ing ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [619] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-waterung ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [620] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-waterjng ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [621] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-waterkng ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [622] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-waterong ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [623] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-water9ng ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [624] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-water8ng ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [625] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-wateribg ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [626] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-waterimg ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [627] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-waterijg ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [628] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-waterihg ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [629] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-waterinf ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [630] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-waterinv ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [631] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-waterinb ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [632] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-waterinh ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [633] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-wateriny ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [634] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-waterint ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [635] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ᰰ£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [636] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering &#u216;£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [637] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering &#i216;£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [638] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ␀£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [639] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ᾴ£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [640] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering &#8q16;£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [641] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering &#8w16;£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [642] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ⁼£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [643] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering •£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [644] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering &#82q6;£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [645] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‗£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [646] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering &#821t;£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [647] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering &#821y;£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [648] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ’£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [649] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£2bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [650] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£qbn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [651] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1vn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [652] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1nn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [653] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1hn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [654] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1gn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [655] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bb-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [656] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bm-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [657] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bj-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [658] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bh-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [659] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn0a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [660] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bnpa-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [661] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-z-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [662] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-s-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [663] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-w-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [664] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-q-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [665] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a0year’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [666] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-apyear’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [667] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-tear’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [668] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-gear’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [669] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-hear’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [670] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-uear’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [671] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-7ear’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [672] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-6ear’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [673] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-ywar’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [674] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-ysar’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [675] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-ydar’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [676] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-yrar’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [677] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-y4ar’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [678] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-y3ar’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [679] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-yezr’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [680] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-yesr’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [681] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-yewr’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [682] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-yeqr’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [683] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-yeae’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [684] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-yead’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [685] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-yeaf’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [686] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-yeat’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [687] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-yea5’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [688] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-yea4’ roll-out cost, but it will be available to private patients who can pay £20,000 a year [689] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-yearᰱ roll-out cost, but it will be available to private patients who can pay £20,000 a year [690] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year&#u217; roll-out cost, but it will be available to private patients who can pay £20,000 a year [691] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year&#i217; roll-out cost, but it will be available to private patients who can pay £20,000 a year [692] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year␁ roll-out cost, but it will be available to private patients who can pay £20,000 a year [693] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year᾵ roll-out cost, but it will be available to private patients who can pay £20,000 a year [694] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year&#8q17; roll-out cost, but it will be available to private patients who can pay £20,000 a year [695] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year&#8w17; roll-out cost, but it will be available to private patients who can pay £20,000 a year [696] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year⁽ roll-out cost, but it will be available to private patients who can pay £20,000 a year [697] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year‣ roll-out cost, but it will be available to private patients who can pay £20,000 a year [698] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year&#82q7; roll-out cost, but it will be available to private patients who can pay £20,000 a year [699] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year‘ roll-out cost, but it will be available to private patients who can pay £20,000 a year [700] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year&#821y; roll-out cost, but it will be available to private patients who can pay £20,000 a year [701] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year&#821u; roll-out cost, but it will be available to private patients who can pay £20,000 a year [702] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year‚ roll-out cost, but it will be available to private patients who can pay £20,000 a year [703] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ eoll-out cost, but it will be available to private patients who can pay £20,000 a year [704] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ doll-out cost, but it will be available to private patients who can pay £20,000 a year [705] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ foll-out cost, but it will be available to private patients who can pay £20,000 a year [706] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ toll-out cost, but it will be available to private patients who can pay £20,000 a year [707] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ 5oll-out cost, but it will be available to private patients who can pay £20,000 a year [708] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ 4oll-out cost, but it will be available to private patients who can pay £20,000 a year [709] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ rill-out cost, but it will be available to private patients who can pay £20,000 a year [710] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ rkll-out cost, but it will be available to private patients who can pay £20,000 a year [711] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ rlll-out cost, but it will be available to private patients who can pay £20,000 a year [712] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ rpll-out cost, but it will be available to private patients who can pay £20,000 a year [713] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ r0ll-out cost, but it will be available to private patients who can pay £20,000 a year [714] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ r9ll-out cost, but it will be available to private patients who can pay £20,000 a year [715] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ rokl-out cost, but it will be available to private patients who can pay £20,000 a year [716] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ ropl-out cost, but it will be available to private patients who can pay £20,000 a year [717] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ rool-out cost, but it will be available to private patients who can pay £20,000 a year [718] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ rolk-out cost, but it will be available to private patients who can pay £20,000 a year [719] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ rolp-out cost, but it will be available to private patients who can pay £20,000 a year [720] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ rolo-out cost, but it will be available to private patients who can pay £20,000 a year [721] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll0out cost, but it will be available to private patients who can pay £20,000 a year [722] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ rollpout cost, but it will be available to private patients who can pay £20,000 a year [723] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-iut cost, but it will be available to private patients who can pay £20,000 a year [724] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-kut cost, but it will be available to private patients who can pay £20,000 a year [725] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-lut cost, but it will be available to private patients who can pay £20,000 a year [726] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-put cost, but it will be available to private patients who can pay £20,000 a year [727] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-0ut cost, but it will be available to private patients who can pay £20,000 a year [728] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-9ut cost, but it will be available to private patients who can pay £20,000 a year [729] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-oyt cost, but it will be available to private patients who can pay £20,000 a year [730] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-oht cost, but it will be available to private patients who can pay £20,000 a year [731] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-ojt cost, but it will be available to private patients who can pay £20,000 a year [732] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-oit cost, but it will be available to private patients who can pay £20,000 a year [733] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-o8t cost, but it will be available to private patients who can pay £20,000 a year [734] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-o7t cost, but it will be available to private patients who can pay £20,000 a year [735] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-our cost, but it will be available to private patients who can pay £20,000 a year [736] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-ouf cost, but it will be available to private patients who can pay £20,000 a year [737] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-oug cost, but it will be available to private patients who can pay £20,000 a year [738] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-ouy cost, but it will be available to private patients who can pay £20,000 a year [739] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-ou6 cost, but it will be available to private patients who can pay £20,000 a year [740] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-ou5 cost, but it will be available to private patients who can pay £20,000 a year [741] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out xost, but it will be available to private patients who can pay £20,000 a year [742] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out vost, but it will be available to private patients who can pay £20,000 a year [743] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out fost, but it will be available to private patients who can pay £20,000 a year [744] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out dost, but it will be available to private patients who can pay £20,000 a year [745] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cist, but it will be available to private patients who can pay £20,000 a year [746] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out ckst, but it will be available to private patients who can pay £20,000 a year [747] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out clst, but it will be available to private patients who can pay £20,000 a year [748] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cpst, but it will be available to private patients who can pay £20,000 a year [749] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out c0st, but it will be available to private patients who can pay £20,000 a year [750] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out c9st, but it will be available to private patients who can pay £20,000 a year [751] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out coat, but it will be available to private patients who can pay £20,000 a year [752] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cozt, but it will be available to private patients who can pay £20,000 a year [753] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out coxt, but it will be available to private patients who can pay £20,000 a year [754] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out codt, but it will be available to private patients who can pay £20,000 a year [755] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out coet, but it will be available to private patients who can pay £20,000 a year [756] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cowt, but it will be available to private patients who can pay £20,000 a year [757] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cosr, but it will be available to private patients who can pay £20,000 a year [758] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cosf, but it will be available to private patients who can pay £20,000 a year [759] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cosg, but it will be available to private patients who can pay £20,000 a year [760] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cosy, but it will be available to private patients who can pay £20,000 a year [761] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cos6, but it will be available to private patients who can pay £20,000 a year [762] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cos5, but it will be available to private patients who can pay £20,000 a year [763] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out costm but it will be available to private patients who can pay £20,000 a year [764] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out costk but it will be available to private patients who can pay £20,000 a year [765] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out costl but it will be available to private patients who can pay £20,000 a year [766] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost. but it will be available to private patients who can pay £20,000 a year [767] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost but it will be available to private patients who can pay £20,000 a year [768] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, vut it will be available to private patients who can pay £20,000 a year [769] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, nut it will be available to private patients who can pay £20,000 a year [770] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, hut it will be available to private patients who can pay £20,000 a year [771] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, gut it will be available to private patients who can pay £20,000 a year [772] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, byt it will be available to private patients who can pay £20,000 a year [773] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, bht it will be available to private patients who can pay £20,000 a year [774] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, bjt it will be available to private patients who can pay £20,000 a year [775] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, bit it will be available to private patients who can pay £20,000 a year [776] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, b8t it will be available to private patients who can pay £20,000 a year [777] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, b7t it will be available to private patients who can pay £20,000 a year [778] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, bur it will be available to private patients who can pay £20,000 a year [779] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, buf it will be available to private patients who can pay £20,000 a year [780] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, bug it will be available to private patients who can pay £20,000 a year [781] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, buy it will be available to private patients who can pay £20,000 a year [782] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, bu6 it will be available to private patients who can pay £20,000 a year [783] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, bu5 it will be available to private patients who can pay £20,000 a year [784] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but ut will be available to private patients who can pay £20,000 a year [785] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but jt will be available to private patients who can pay £20,000 a year [786] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but kt will be available to private patients who can pay £20,000 a year [787] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but ot will be available to private patients who can pay £20,000 a year [788] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but 9t will be available to private patients who can pay £20,000 a year [789] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but 8t will be available to private patients who can pay £20,000 a year [790] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but ir will be available to private patients who can pay £20,000 a year [791] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but if will be available to private patients who can pay £20,000 a year [792] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but ig will be available to private patients who can pay £20,000 a year [793] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but iy will be available to private patients who can pay £20,000 a year [794] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but i6 will be available to private patients who can pay £20,000 a year [795] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but i5 will be available to private patients who can pay £20,000 a year [796] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it qill be available to private patients who can pay £20,000 a year [797] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it aill be available to private patients who can pay £20,000 a year [798] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it sill be available to private patients who can pay £20,000 a year [799] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it eill be available to private patients who can pay £20,000 a year [800] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it 3ill be available to private patients who can pay £20,000 a year [801] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it 2ill be available to private patients who can pay £20,000 a year [802] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it wull be available to private patients who can pay £20,000 a year [803] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it wjll be available to private patients who can pay £20,000 a year [804] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it wkll be available to private patients who can pay £20,000 a year [805] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it woll be available to private patients who can pay £20,000 a year [806] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it w9ll be available to private patients who can pay £20,000 a year [807] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it w8ll be available to private patients who can pay £20,000 a year [808] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it wikl be available to private patients who can pay £20,000 a year [809] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it wipl be available to private patients who can pay £20,000 a year [810] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it wiol be available to private patients who can pay £20,000 a year [811] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it wilk be available to private patients who can pay £20,000 a year [812] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it wilp be available to private patients who can pay £20,000 a year [813] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it wilo be available to private patients who can pay £20,000 a year [814] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will ve available to private patients who can pay £20,000 a year [815] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will ne available to private patients who can pay £20,000 a year [816] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will he available to private patients who can pay £20,000 a year [817] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will ge available to private patients who can pay £20,000 a year [818] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will bw available to private patients who can pay £20,000 a year [819] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will bs available to private patients who can pay £20,000 a year [820] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will bd available to private patients who can pay £20,000 a year [821] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will br available to private patients who can pay £20,000 a year [822] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will b4 available to private patients who can pay £20,000 a year [823] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will b3 available to private patients who can pay £20,000 a year [824] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be zvailable to private patients who can pay £20,000 a year [825] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be svailable to private patients who can pay £20,000 a year [826] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be wvailable to private patients who can pay £20,000 a year [827] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be qvailable to private patients who can pay £20,000 a year [828] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be acailable to private patients who can pay £20,000 a year [829] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be abailable to private patients who can pay £20,000 a year [830] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be agailable to private patients who can pay £20,000 a year [831] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be afailable to private patients who can pay £20,000 a year [832] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be avzilable to private patients who can pay £20,000 a year [833] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be avsilable to private patients who can pay £20,000 a year [834] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be avwilable to private patients who can pay £20,000 a year [835] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be avqilable to private patients who can pay £20,000 a year [836] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be avaulable to private patients who can pay £20,000 a year [837] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be avajlable to private patients who can pay £20,000 a year [838] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be avaklable to private patients who can pay £20,000 a year [839] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be avaolable to private patients who can pay £20,000 a year [840] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be ava9lable to private patients who can pay £20,000 a year [841] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be ava8lable to private patients who can pay £20,000 a year [842] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be avaikable to private patients who can pay £20,000 a year [843] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be avaipable to private patients who can pay £20,000 a year [844] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be avaioable to private patients who can pay £20,000 a year [845] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be availzble to private patients who can pay £20,000 a year [846] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be availsble to private patients who can pay £20,000 a year [847] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be availwble to private patients who can pay £20,000 a year [848] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be availqble to private patients who can pay £20,000 a year [849] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be availavle to private patients who can pay £20,000 a year [850] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be availanle to private patients who can pay £20,000 a year [851] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be availahle to private patients who can pay £20,000 a year [852] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be availagle to private patients who can pay £20,000 a year [853] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be availabke to private patients who can pay £20,000 a year [854] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be availabpe to private patients who can pay £20,000 a year [855] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be availaboe to private patients who can pay £20,000 a year [856] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be availablw to private patients who can pay £20,000 a year [857] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be availabls to private patients who can pay £20,000 a year [858] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be availabld to private patients who can pay £20,000 a year [859] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be availablr to private patients who can pay £20,000 a year [860] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be availabl4 to private patients who can pay £20,000 a year [861] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be availabl3 to private patients who can pay £20,000 a year [862] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available ro private patients who can pay £20,000 a year [863] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available fo private patients who can pay £20,000 a year [864] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available go private patients who can pay £20,000 a year [865] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available yo private patients who can pay £20,000 a year [866] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available 6o private patients who can pay £20,000 a year [867] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available 5o private patients who can pay £20,000 a year [868] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available ti private patients who can pay £20,000 a year [869] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available tk private patients who can pay £20,000 a year [870] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available tl private patients who can pay £20,000 a year [871] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available tp private patients who can pay £20,000 a year [872] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available t0 private patients who can pay £20,000 a year [873] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available t9 private patients who can pay £20,000 a year [874] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to orivate patients who can pay £20,000 a year [875] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to lrivate patients who can pay £20,000 a year [876] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to -rivate patients who can pay £20,000 a year [877] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to 0rivate patients who can pay £20,000 a year [878] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to peivate patients who can pay £20,000 a year [879] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to pdivate patients who can pay £20,000 a year [880] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to pfivate patients who can pay £20,000 a year [881] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to ptivate patients who can pay £20,000 a year [882] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to p5ivate patients who can pay £20,000 a year [883] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to p4ivate patients who can pay £20,000 a year [884] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to pruvate patients who can pay £20,000 a year [885] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to prjvate patients who can pay £20,000 a year [886] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to prkvate patients who can pay £20,000 a year [887] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to provate patients who can pay £20,000 a year [888] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to pr9vate patients who can pay £20,000 a year [889] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to pr8vate patients who can pay £20,000 a year [890] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to pricate patients who can pay £20,000 a year [891] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to pribate patients who can pay £20,000 a year [892] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to prigate patients who can pay £20,000 a year [893] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to prifate patients who can pay £20,000 a year [894] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to privzte patients who can pay £20,000 a year [895] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to privste patients who can pay £20,000 a year [896] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to privwte patients who can pay £20,000 a year [897] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to privqte patients who can pay £20,000 a year [898] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to privare patients who can pay £20,000 a year [899] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to privafe patients who can pay £20,000 a year [900] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to privage patients who can pay £20,000 a year [901] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to privaye patients who can pay £20,000 a year [902] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to priva6e patients who can pay £20,000 a year [903] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to priva5e patients who can pay £20,000 a year [904] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to privatw patients who can pay £20,000 a year [905] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to privats patients who can pay £20,000 a year [906] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to privatd patients who can pay £20,000 a year [907] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to privatr patients who can pay £20,000 a year [908] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to privat4 patients who can pay £20,000 a year [909] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to privat3 patients who can pay £20,000 a year [910] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private oatients who can pay £20,000 a year [911] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private latients who can pay £20,000 a year [912] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private -atients who can pay £20,000 a year [913] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private 0atients who can pay £20,000 a year [914] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private pztients who can pay £20,000 a year [915] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private pstients who can pay £20,000 a year [916] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private pwtients who can pay £20,000 a year [917] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private pqtients who can pay £20,000 a year [918] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private parients who can pay £20,000 a year [919] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private pafients who can pay £20,000 a year [920] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private pagients who can pay £20,000 a year [921] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private payients who can pay £20,000 a year [922] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private pa6ients who can pay £20,000 a year [923] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private pa5ients who can pay £20,000 a year [924] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patuents who can pay £20,000 a year [925] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patjents who can pay £20,000 a year [926] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patkents who can pay £20,000 a year [927] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patoents who can pay £20,000 a year [928] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private pat9ents who can pay £20,000 a year [929] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private pat8ents who can pay £20,000 a year [930] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patiwnts who can pay £20,000 a year [931] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patisnts who can pay £20,000 a year [932] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patidnts who can pay £20,000 a year [933] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patirnts who can pay £20,000 a year [934] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private pati4nts who can pay £20,000 a year [935] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private pati3nts who can pay £20,000 a year [936] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patiebts who can pay £20,000 a year [937] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patiemts who can pay £20,000 a year [938] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patiejts who can pay £20,000 a year [939] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patiehts who can pay £20,000 a year [940] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patienrs who can pay £20,000 a year [941] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patienfs who can pay £20,000 a year [942] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patiengs who can pay £20,000 a year [943] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patienys who can pay £20,000 a year [944] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patien6s who can pay £20,000 a year [945] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patien5s who can pay £20,000 a year [946] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patienta who can pay £20,000 a year [947] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patientz who can pay £20,000 a year [948] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patientx who can pay £20,000 a year [949] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patientd who can pay £20,000 a year [950] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patiente who can pay £20,000 a year [951] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patientw who can pay £20,000 a year [952] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients qho can pay £20,000 a year [953] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients aho can pay £20,000 a year [954] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients sho can pay £20,000 a year [955] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients eho can pay £20,000 a year [956] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients 3ho can pay £20,000 a year [957] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients 2ho can pay £20,000 a year [958] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients wgo can pay £20,000 a year [959] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients wbo can pay £20,000 a year [960] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients wno can pay £20,000 a year [961] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients wjo can pay £20,000 a year [962] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients wuo can pay £20,000 a year [963] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients wyo can pay £20,000 a year [964] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients whi can pay £20,000 a year [965] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients whk can pay £20,000 a year [966] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients whl can pay £20,000 a year [967] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients whp can pay £20,000 a year [968] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients wh0 can pay £20,000 a year [969] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients wh9 can pay £20,000 a year [970] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who xan pay £20,000 a year [971] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who van pay £20,000 a year [972] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who fan pay £20,000 a year [973] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who dan pay £20,000 a year [974] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who czn pay £20,000 a year [975] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who csn pay £20,000 a year [976] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who cwn pay £20,000 a year [977] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who cqn pay £20,000 a year [978] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who cab pay £20,000 a year [979] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who cam pay £20,000 a year [980] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who caj pay £20,000 a year [981] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who cah pay £20,000 a year [982] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can oay £20,000 a year [983] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can lay £20,000 a year [984] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can -ay £20,000 a year [985] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can 0ay £20,000 a year [986] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pzy £20,000 a year [987] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can psy £20,000 a year [988] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pwy £20,000 a year [989] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pqy £20,000 a year [990] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pat £20,000 a year [991] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pag £20,000 a year [992] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pah £20,000 a year [993] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pau £20,000 a year [994] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pa7 £20,000 a year [995] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pa6 £20,000 a year [996] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £10,000 a year [997] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £q0,000 a year [998] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £w0,000 a year [999] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £30,000 a year [1000] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £29,000 a year [1001] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £2o,000 a year [1002] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £2p,000 a year [1003] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £2-,000 a year [1004] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20m000 a year [1005] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20k000 a year [1006] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20l000 a year [1007] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20.000 a year [1008] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20 000 a year [1009] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,900 a year [1010] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,o00 a year [1011] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,p00 a year [1012] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,-00 a year [1013] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,090 a year [1014] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,0o0 a year [1015] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,0p0 a year [1016] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,0-0 a year [1017] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,009 a year [1018] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,00o a year [1019] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,00p a year [1020] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,00- a year [1021] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 z year [1022] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 s year [1023] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 w year [1024] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 q year [1025] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a tear [1026] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a gear [1027] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a hear [1028] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a uear [1029] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a 7ear [1030] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a 6ear [1031] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a ywar [1032] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a ysar [1033] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a ydar [1034] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a yrar [1035] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a y4ar [1036] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a y3ar [1037] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a yezr [1038] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a yesr [1039] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a yewr [1040] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a yeqr [1041] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a yeae [1042] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a yead [1043] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a yeaf [1044] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a yeat [1045] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a yea5 [1046] => ‘miracle’ alzheimer’s drug won’t be offered on the nhs after drug watchdog rules benefits are too small to justify the eye-watering ‘£1bn-a-year’ roll-out cost, but it will be available to private patients who can pay £20,000 a yea4 ) </h1> </body>